^
Association details:
| Biomarker: | CD20 positive + TMB-L |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study
Published date:
04/18/2023
Excerpt:
Patients with histologically confirmed CD20+ low–tumor burden FL were randomly assigned to receive either rituximab...The primary end point was met: the 4-year PFS was 58.1% (95% CI, 47.5 to 67.4) and 41.2% (95% CI, 30.6 to 51.6) in experimental and control arms, respectively (hazard ratio, 0.585 [0.393 to 0.871]; P = .0076). Complete response (CR) rates were 59.0% (95% CI, 48.7 to 68.7) in the experimental arm...SC rituximab improves PFS for patients with low-tumor burden FL when used in induction followed by short maintenance.
DOI:
10.1200/JCO.22.02327
Trial ID:
